RareResearch.AI
← Back to atlas

A598T

Category 4 — Stable Fold, Function DisruptedConflictingTransmembrane · predictedEditorial
AlanineThreonine at position 598 · TM9 (589-609), helical transmembrane · WFS1 (Wolframin)

Ala→Thr p598 TM9 AM=0.09 ddg=+0.12 pLDDT=69. ClinVar Conflicting evidence. Atlas mechanism: see structural analysis.

Interactive 3D Structure

Wild-type reference
Wild-type A598 — hydrogen bond to L594
Fullscreen ↗
DynaMut2 mutant · A598T
Mutant T598 — hydrogen bond contact to T595 lost
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

0 lost0 gained6 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondL594L594Preserved
Hydrogen bondT595T595Preserved
Hydrogen bondA602A602Preserved
Polar contactL594L594Preserved
Polar contactT595T595Preserved
Polar contactA602A602Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
0.12kcal/mol
Stabilising — mild
AlphaMissense
0.085
LBen
AlphaFold pLDDT
69
model confidence
Schema
Cat 4
Category 4 — Stable Fold, Function Disrupted
ΔΔG confidence: Low confidence · Transmembrane
  • transmembrane position; predictor benchmarked on soluble proteins
  • pLDDT 68.75 below 70

This variant sits in the transmembrane band. The stability value was computed with a predictor benchmarked on water-soluble proteins. Published benchmarks of ddG predictors on membrane proteins report correlation below 0.4. Treat the magnitude as unreliable and the sign as weak evidence only.

The underlying AlphaFold model has pLDDT below 70 at this position, so the structure the stability calculation was run on is itself uncertain.

Do not rank this value against a variant from a different region on ΔΔG alone.

Clinical Evidence

ClinVar classificationConflicting classifications of pathogenicity
Review statuscriteria provided, conflicting classifications
Associated conditions(no specific conditions catalogued)
InheritanceConflicting ClinVar classifications.
Population frequency (gnomAD v4)Low frequency · AF 0.015%
cDNA changec.1792G>A
ClinVar accessionVCV000178596
Last evaluated2025/12/20 00:00

Observed in the general population.

Classified for1★ unverified submission

ClinVar classifies this variant as Conflicting classifications of pathogenicity for WFS1-related spectrum (unresolved mode) (dominant or recessive); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300). ClinVar records this under a WFS1-spectrum label that spans both disease families — recessive Wolfram syndrome (biallelic) and the dominant WFS1-related disorders. The label does not resolve which applies, and it is not a severity statement.

  • WFS1-related spectrum (unresolved mode)dominant or recessivesubmitted as: WFS1-Related Spectrum Disorders
  • Nonsyndromic hearing loss (DFNA6/14/38)autosomal dominant · OMIM 600965submitted as: Autosomal dominant nonsyndromic hearing loss 6
  • Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1
  • Submitters conflict on this classification (1★). Treat the conditions above as submitted, not as documented phenotypes.
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ conflicting classifications. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.015% · 238 / 1,614,158 alleles
Homozygotes
1
Highest-frequency population
African / African American · AF 0.237%

Highest in African / African American: AF 0.237% (178 of 75,064 alleles), 16.1x the global figure. The global AF describes the general population, not the at-risk group.

1 homozygote reported in gnomAD v4 (1 South Asian). gnomAD excludes individuals with severe pediatric disease, so homozygotes in this dataset argue against a fully penetrant severe recessive phenotype and belong in the clinical picture. This is interpretive signal, not a classification.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
African / African American0.237%178 / 75,0640~1 in 210
Admixed American0.023%14 / 60,0300~1 in 2140
Remaining individuals0.019%12 / 62,5120~1 in 2600
South Asian0.019%17 / 91,0801~1 in 2680
Middle Eastern · under-sampled0.016%1 / 6,0620
Finnish · under-sampled0.0016%1 / 63,9820
European (non-Finnish)0.0013%15 / 1,180,0440~1 in 39330

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Structural Context

Position analysis: ILE597 (2.5 Å), VAL599 (2.5 Å), THR595 (3.9 Å — A598T-T595 H-bond possible). TM9 cluster (with L592V/P607L/R, E593D, V601M). The Atlas's neighbor extraction surfaces this variant's contacts.

Amino-acid chemistry
polarity into bilayer
Position in the protein
TM9 (589-609)

Druggability Assessment

Cat 4 — see structural prose. AlphaMissense below threshold (AM under-call class) but mechanism is structurally clear from neighbor analysis. Therapeutic strategy: site-directed at the contacts identified above.

Why this matters

TM9 multi-variant cluster.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the A598T PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download A598T PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Transmembrane589609 · Helical